ESR1 and breast carcinoma: Actually, in ER+ breast cancer, IGF‐1/AKT/mTOR signalling pathway interacting with oestrogen receptor (ER) signalling becomes more complicated and interdependent with acquired endocrine resistance (Fig. 7) 14.